National/ International Desk
1 May
Sandeep Dhand Ludhiana
AstraZeneca, the developer and manufacturer of the Covishield Covid vaccine, recently disclosed that the vaccine could potentially lead to Thrombosis with Thrombocytopenia Syndrome (TTS) as a side effect in some individuals. This revelation has sparked discussions on social media platforms, with some posts claiming that most Indians are now at risk of TTS. However, a fact check by The Healthy Indian Project (THIP) has revealed that while the risk of TTS exists, the probability of experiencing this side effect is deemed “very rare.”
Several social media posts have criticized the Indian government for allowing the Covishield vaccine in the country, alleging that it puts people at risk of vaccination-induced TTS. These allegations are based on AstraZeneca’s acknowledgment in a UK court regarding the potential rare side effects of their vaccines.
However, it is essential to note that while the risk exists, the probability of experiencing TTS after receiving the Covishield vaccine is considered to be very low. The Indian government continues to monitor and address any concerns regarding vaccine safety, emphasizing the importance of vaccination in combating the Covid-19 pandemic while ensuring public health and safety.